Search

Displaying results 2411 - 2420 of 8009 in total
  1. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and … safer for use in patients with contraindications to standard therapy.

  2. Drug

    Uprifosbuvir

    go.drugbank.com/drugs/DB15206
    Investigational

    Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis … C Genotype (GT)1 and GT2 Infection (MK-3682-011)).

  3. Indication

    Lymphoblastic Lymphoma

    go.drugbank.com/conditions/DBCOND0032667
    Drugs: Asparaginase Erwinia chrysanthemi · Mercaptopurine
    Synonyms: Non-Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype
  4. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    It is available in topical formulations for the treatment of skin infections such as athlete's foot.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  6. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    [L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair

  7. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in

    Categories: Agents for Dermatitis, Excluding Corticosteroids
  8. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. … Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation.

  9. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of … Deficiency of C1-inhibitor allows for increased plasma kallikrein activation and subsequent production of bradykinin.

    Products: RUCONEST 2100 U IV ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  10. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that

    Categories: Compounds used in a research, industrial, or household setting